Colestipol hydrochloride.JPG

Colestipol hydrochloride

CLINICAL USE

Hyperlipidaemias, particularly type IIa

DOSE IN NORMAL RENAL FUNCTION

5 g once or twice daily, increased if necessary at intervals of 1–2 months, to a maximum of 30 g daily

PHARMACOKINETICS

  • Molecular weight                           :–
  • %Protein binding                           :0
  • %Excreted unchanged in urine     : 0
  • Volume of distribution (L/kg)       :Not absorbed
  • half-life – normal/ESRD (hrs)      :Not absorbed

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as in normal renal function
  • HDF/high flux   :Not dialysed. Dose as in normal renal function
  • CAV/VVHD      :Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAnticoagulants: may enhance or reduce effects of coumarins and phenindioneCiclosporin: No reports of an interaction; however, ciclosporin levels should be carefully monitored if colestipol and ciclosporin are prescribed concurrently, as colestipol may interfere with ciclosporin absorption

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible interference with absorptionColestipol granules may be administered as a suspension in water or a flavoured vehicleColestipol orange contains 32.5 mg aspartame (18.2 mg phenylalanine) per sachet

    OTHER INFORMATION

    Colestipol may interfere with the absorption of fat soluble vitamins